Skip to content

Safety and Efficacy of One Dose Prophylactic Antibiotic in Laparoscopic Colorectal Surgery

Phase 2 Study of One Dose Prophylactic Antibiotic in Laparoscopic Colorectal Surgery

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01220661
Enrollment
312
Registered
2010-10-14
Start date
2010-10-31
Completion date
2011-12-31
Last updated
2011-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Surgery

Keywords

Colorectal Surgery, Surgical Wound Infection, Laparoscopy, Anti-Bacterial Agents

Brief summary

In colorectal surgery, the use of prophylactic antibiotics is recommended. The standard use of antibiotics for colorectal surgery is three doses. It has been reported that the surgical site infection rates of laparoscopic colorectal surgery are lower than open colorectal surgery. However, the evidence of proper application of antibiotic for laparoscopic colorectal surgery is still not enough. The investigators are researching the efficacy and safety of one dose prophylactic antibiotic in laparoscopic colorectal surgery.

Detailed description

In colorectal surgery, the use of prophylactic antibiotics is recommended. The standard use of antibiotics for colorectal surgery is three doses. One randomized controlled study reported that surgical site infection rates of three doses prophylactic antibiotics are lower than those of one dose in colorectal surgery (4.3 versus 14.2%). But, surgical site infection rates between one dose and three doses were not different in laparoscopic subgroup of this study (11 versus 11%) It has been reported that the surgical site infection rates of laparoscopic colorectal surgery are lower than open colorectal surgery. However, the evidence of proper application of antibiotic for laparoscopic colorectal surgery is still not enough. The investigators are researching the efficacy and safety of one dose prophylactic antibiotic in laparoscopic colorectal surgery.

Interventions

preoperative one dose prophylactic antibiotic (2g iv, within 1 hour before skin incision)

Sponsors

National Cancer Center, Korea
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients have laparoscopic colorectal surgery for cancer at National Cancer Center * Patients should sign a written informed consent * Age between 18-80 years * Adequate bone marrow function Hb ≥ 10g/dl (after treatment for simple iron deficiency anemia) WBC ≥ 3,000/mm3 PLT ≥ 100,000/mm3 * Adequate kidney function Creatinine ≤ 1.5 mg/dl * No remarkable evidence of heart dysfunction and lung dysfunction

Exclusion criteria

* Patients undergo emergency surgery with multiple symptoms * Open colorectal surgery for cancer or conversion to an open procedure * Patients who undergo only ostomy surgery * Palliative surgery * Surgery combined with other organs * Patients on treatment with recurred cancer * Patients who have active bacterial infection and required parenteral antibiotics * Patients have an allergy to Cefoxitin * Other organ cancer history(except who had radical excision for skin cancer) * Presence of other serious disease * Mentally ill patients * Legally unable to participate in clinical trial * Lactating or pregnant women * Patients who will obviously fail to regular follow-up visit or will be off study voluntarily * Not eligible to participate for other reasons by doctor's decision

Design outcomes

Primary

MeasureTime frameDescription
Surgical site infectionThree weeks after surgeryany surgical infections (superficial incisional infection or infection of deep incision space or organ space infection)

Secondary

MeasureTime frameDescription
Overall infectionThree weeks after surgeryOverall infection including surgical site infection, pneumonia, urinary tract infection etc.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026